Valuation: Simcere Pharmaceutical Group Limited

Market Cap 404.47Cr 3.17TCr 351.61Cr 327.27Cr 300.48Cr 567.42Cr 39TCr 576.21Cr 3.86TCr 1.51TCr 19TCr 1.52TCr 1.49TCr 64TCr P/E 2026 *
16x
P/E 2027 * 13.9x
Enterprise Value 385.79Cr 3.03TCr 335.36Cr 312.15Cr 286.59Cr 541.21Cr 37TCr 549.59Cr 3.68TCr 1.44TCr 18TCr 1.45TCr 1.42TCr 61TCr EV / Sales 2026 *
2.58x
EV / Sales 2027 * 2.37x
Free-Float
32.48%
Yield 2026 *
3.33%
Yield 2027 * 3.83%
30/07 Simcere Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2026 CI
09/07 Simcere Pharma's Acute Ischemic Stroke Included in National Essential Medicines List MT
15/06 Simcere Pharma Gets China Nod for Tumor Drug Trial MT
12/06 Simcere Pharmaceutical Group Limited Receives Clinical Trial Approval for Sim0689 Pd-1/Vegf Bispecific Antibody CI
12/06 Simcere Pharmaceutical Group Limited Approves Final Dividend for the Year Ended December 31, 2025, Payable on or Before July 13, 2026 CI
12/06 Simcere Pharmaceutical Group Limited Enters into A Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis CI
02/06 Simcere Pharma Wins Promotion Rights for PrimeGenX's Atopic Dermatitis Drug MT
01/06 Simcere Pharmaceutical Group Limited Enters into Exclusive Promotion Service Agreement with PrimeGenX Therapeutics Co., Ltd CI
21/05 Simcere Pharmaceutical Group Limited Proposes to Declare A Final Dividend for the Year Ended December 31, 2025 CI
06/05 Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for SIM0613 LRRC15 Antibody Drug Conjugate CI
06/05 Simcere pharmaceutical receives NMPA China clinical trial approval for SIM0613 RE
06/05 Simcere Pharmaceutical Receives Chinese Regulatory Approval to Begin Trials of Tumor Drug MT
04/05 Wuxi Biocity Biopharmaceutics Co., Ltd. announced that it has received funding from Simcere Pharmaceutical Group Limited, First Light Capital CI
1 day-1.78%
1 week-3.88%
Current month-1.78%
1 month+5.75%
3 months+1.85%
6 months+6.22%
Current year+1.34%
1 week 12.08
Extreme 12.08
13.12
1 month 11.34
Extreme 11.34
13.52
Current year 9.07
Extreme 9.07
14.28
1 year 9.07
Extreme 9.07
15.08
3 years 4.94
Extreme 4.94
15.08
5 years 4.94
Extreme 4.94
15.08
10 years 4.94
Extreme 4.94
15.08
Manager TitleAgeSince
Chief Executive Officer 54 25/03/2026
Director of Finance/CFO 55 19/11/2019
Chief Tech/Sci/R&D Officer 51 01/12/2023
Director TitleAgeSince
Chairman 63 08/10/2012
Director/Board Member 55 19/11/2019
Director/Board Member 46 01/11/2019
Date Insider Type Main position Quantity % Market Cap.
13/07/26 Other

Founder

-47,000 0.0018%
13/07/26 Other

Director

-47,000 0.0018%
10/07/26 Other

Founder

-53,000 0.0021%
Change 5-day change 1-year change 3-year change Capi.($)
-1.78%-3.88%-2.65%+68.71% 404.47Cr
-0.53%+2.54%+22.14%+75.34% 5TCr
+2.25%+0.22%+54.13%+115.78% 3.66TCr
+0.46%+4.44%-1.97%+26.10% 1.25TCr
+1.05%+1.63%+18.73%+79.26% 1.18TCr
-1.33%-0.76%+30.73%+130.67% 903.81Cr
-2.01%-4.24%+41.36%-11.92% 702.99Cr
+0.51%+1.46%+13.46%+32.66% 679.37Cr
+1.99%+1.91%+8.03%+186.16% 660.39Cr
+0.39%+3.39%-35.25%+8.97% 549.26Cr
Average +0.10%+0.57%+14.87%+71.17% 1.5TCr
Weighted average by Cap. +0.40%+1.16%+25.31%+81.01%

Financials

2026 *2027 *
Net sales 149.43Cr 1.17TCr 129.9Cr 120.91Cr 111.01Cr 209.63Cr 14TCr 212.87Cr 1.43TCr 559.34Cr 7.1TCr 561.19Cr 548.86Cr 24TCr 165.71Cr 1.3TCr 144.05Cr 134.08Cr 123.1Cr 232.46Cr 16TCr 236.06Cr 1.58TCr 620.27Cr 7.88TCr 622.32Cr 608.65Cr 26TCr
Net income 25Cr 192.91Cr 21Cr 20Cr 18Cr 35Cr 2.35TCr 35Cr 234.64Cr 92Cr 1.17TCr 92Cr 90Cr 3.92TCr 28Cr 219.76Cr 24Cr 23Cr 21Cr 39Cr 2.68TCr 40Cr 267.29Cr 104.9Cr 1.33TCr 105.25Cr 102.94Cr 4.47TCr
Net Debt -19Cr -146.54Cr -16Cr -15Cr -14Cr -26Cr -1.78TCr -27Cr -178.24Cr -70Cr -888.14Cr -70Cr -69Cr -2.98TCr -12Cr -96Cr -11Cr -9.92Cr -9.11Cr -17Cr -1.17TCr -17Cr -116.91Cr -46Cr -582.54Cr -46Cr -45Cr -1.95TCr
Logo Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Ltd is a company engaged in research and development, production and sales of drugs. The Company's main products are generic drugs, including Bicun used for central nervous system diseases, Jepaso and Jiebaili used for oncology, as well as Yingtaiqing used for autoimmune diseases. The Company also produces various drugs, including Endostar used for oncology. The Company is also involved in providing promotion services for third-party drugs sold by medical institutions. The Company mainly conducts its businesses in the domestic market and overseas markets.
Employees
7,038
Date Price Change Volume
03/26/03 HK$12.13 -1.78% 16,00,000
31/26/31 HK$12.35 -1.28% 80,92,701
30/26/30 HK$12.51 -2.72% 38,40,000
29/26/29 HK$12.86 +0.39% 41,93,281
28/26/28 HK$12.81 +1.51% 53,20,000
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
10.64CNY
Average target price
15.33CNY
Spread / Average Target
+44.13%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 2096 Stock